美国血液技术 HAE 深 沪
已收盘 02-06 16:00:00 美东时间
59.34
-5.680
-8.74%
华盛通- 最 高66.085
- 今 开65.19
- 成交量 202.26万股
- 最 低 59.04
- 昨 收 65.02
- 总市值 27.78亿
- 52周最高 87.32
- 市盈率 静 17.95
- 换手率 4.32%
- 52周最低 47.315
- 委 比 28.62%
- 总股本 4680.97万
- 历史最高 142.11
- 量 比 1.78
- 振 幅 10.84%
- 历史最低 25.98
- 每 手 1
- 风险率 10.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多财报速睇 | 美国血液技术2026财年Q3营收3.39亿美元，同比下降2.7%；归母净利润0.45亿美元，同比增长19.3%
华盛资讯2月7日讯，美国血液技术公布2026财年Q3业绩，公司Q3营收3.39亿美元，同比下降2.7%，归母净利润0.45亿美元，同比增长19.3%。
今天 08:20
财报速睇 | 美国血液技术 2025财年Q4营收3.39亿美元，同比下降2.7%；归母净利润0.45亿美元，同比增长19.3%
华盛资讯2月6日讯，美国血液技术公布2025财年Q4业绩，公司Q4营收3.39亿美元，同比下降2.7%，归母净利润0.45亿美元，同比增长19.3%。
02-06 15:42
Haemonetics Sees Revenue for 2026 FY is expected to down by -3 to -1% YoY
Haemonetics (NYSE:HAE) sees Revenue for 2026 FY is expected to down by -3 to -1% YoY
02-05 20:25
Earnings Scheduled For February 5, 2026
Companies Reporting Before The Bell • WEC Energy Group (NYSE:WEC) is estimated ...
02-05 19:11
Haemonetics Raises FY2026 Adj EPS Guidance from $4.80-$5.00 to $4.90-$5.00 vs $4.91 Est
Haemonetics (NYSE:HAE) raises FY2026 Adj EPS guidance from $4.80-$5.00 to $4.90-$5.00 vs $4.91 analyst estimate..
02-05 19:06
Insights into Haemonetics Q3 Earnings
Haemonetics (NYSE:HAE) just disclosed its Q3 earnings on Thursday, February 5, ...
02-05 19:06
Haemonetics Q3 Adj. EPS $1.31 Beats $1.25 Estimate, Sales $338.967M Beat $331.616M Estimate
Haemonetics (NYSE:HAE) reported quarterly earnings of $1.31 per share which beat the analyst consensus estimate of $1.25 by 4.8 percent. This is a 10.08 percent increase over earnings of $1.19 per share from the same
02-05 19:04
美股大行评级 | 高露洁棕榄、再生元制药、伊士曼化工、威瑞森、Ameris、丘奇＆德怀特等获多家大行上调目标价
今日重点评级关注：Benchmark：维持Charter Communications"买入"评级，目标价从425美元升至455美元；BTIG：维持LifeStance Health Gr"买入"评级，目标价从10美元升至11美元
02-03 09:06
A Glimpse Into The Expert Outlook On Haemonetics Through 11 Analysts
Providing a diverse range of perspectives from bullish to bearish, 11 analysts ...
02-02 21:01
Barrington Research Maintains Outperform on Haemonetics, Maintains $93 Price Target
Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and maintains $93 price target.
02-02 20:51
